Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia

Bone Marrow Transplantation

Volumn 19, Issue 7, 1997, Pages 679-683

  Roman J ^a   Martin C ^a   Torres, A ^a   Jimenez M A ^a   Andres P ^a   Flores, R ^a   De La Torre, M J ^a   Sanchez J ^a   Serrano, J ^a   Falcon M ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Acute promyelocytic leukemia; BMT; PML RAR

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE FUSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RECEPTOR GENE; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION;

EID: 0030980533     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700712     Document Type: Article

References (29)

1. Kakizuka A, Miller W, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
2. Alcalay M, Zangrilli D, Fagioli M et al. Expression pattern of the RARα-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 4840-4844.
3. Pandolfi PP, Alcalay M, Fagioli M et al. Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukemia. EMBO J 1992; 1: 1397-1407.
4. Miller WH Jr, Kakizuka A. Frankel SR et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-2698.
5. Biondi A, Rambaldi A, Pandolfi PP et al. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
6. Castaigne S, Balitrand N, de Thé H et al. A PML/retinoic acid receptor-a fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79: 3110-3115.
7. Chen SJ, Chen Z, Chen A et al. Occurrence of distinct PML-RARα fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene 1992; 7: 1223-1232.
8. Borrow J, Goddard AD, Gibbons B et al. Diagnosis of acute promyelocytic leukemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992; 82: 529-540.
9. Chang K-S, Lu J, Wang G et al. The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction. Blood 1992; 79: 554-558.
10. Lo Coco F, Diverio D, Pandolfi PP et al. Molecular evaluation of residual disease as predictor of relapse in acute promyelocytic leukemia. Lancet 1992; 340: 1437-1438.
11. Miller WH Jr, Levine K, De Blasio A et al. Detection of minimal residual disease in acute promyelocytic leukemia by reverse transcriptase polymerase chain reaction assay for PML-RARα fusion mRNA. Blood 1993; 82: 1689-1694.
12. Huang W, Sun GL, Li XS et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase polymerase chain reaction to predict relapse. Blood 1993; 82: 1264-1269.
13. Diverio D, Pandolfi PP, Rossi V et al. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia 1994; 8: 1105-1107.
14. Koller E, Karlic H, Krieger O et al. Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia. Ann Hematol 1995; 70: 75-78.
15. Fukutani H, Naoe T, Ohno R et al for the Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. Leukemia 1995; 9: 588-593.
16. Mandelli F, Labopin M, Grañena A et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Bone Marrow Transplant 1994; 14: 293-298.
17. Lo Coco F, Avvisati G, Diverio D et al. Molecular evaluation of response to all-trans retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 1991; 77: 1657-1659.
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation. Ann Biochem 1987; 162: 156-159.
19. Xu WM, Piao XH, Addy L et al. Minimal residual disease in bone marrow transplant recipients with chronic myeloid leukemia. Bone Marrow Transplant 1994; 14: 299-306.
20. Van Rhee F, Lin F, Cross NCP et al. Detection of residual leukemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transplant 1994; 14: 609-612.
21. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712-715.
22. Lee MS, Kartarjian H, Talpaz M et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following Interferon therapy. Blood 1992; 79: 1920-1923.
23. Lo Coco F, Mandelli F, Diverio D et al. Therapy-induced Ph′ suppression in chronic myeloid leukemia. Molecular and cytogenetic studies in patients treated with α-2b interferon, high-dose chemotherapy and autologous stem cell infusion. Bone Marrow Transplant 1990; 6: 253-258.
24. Levine K, DeBlasio A, Miller WH Jr. Molecular diagnosis and monitoring of acute promyelocytic leukemia treated with retinoic acid. Leukemia 1994; 8 (Suppl. 1): S116-S120.
25. Laczika K, Mitterbauer G, Korninger L et al. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-trans retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia 1994; 8: 1-5.
26. Diverio D, Pandolfi PP, Biondi A et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993; 82: 3556-3559.
27. Martinelli G, Remiddi C, Visani G et al. Molecular analysis of PML-RARα fusion mRNA detected by reverse transcriptionpolymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients. Br J Haematol 1995; 90: 966-968.
28. Tobal K, Saunders MJ, Grey MR, Yin JAL. Persistence of RARα-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukemia. Br J Haematol 1995; 90: 615-618.
29. Miyamura K, Barret AJ, Kodera Y, Saito H. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results. Bone Marrow Transplant 1994; 14: 201-209.